Pursuant to provision of Regulation 30 of LODR, Nomination and Remuneration Committee has approved grant of 75000 Options to the Eligible Employee under "Global space Technologies Limited ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Globalspace Technologies' board, meeting on May 23, 2025, approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025. On a standalone basis, FY25 revenue from operations was Rs 2,932.48 lakhs vs Rs 2,904.80 lakhs last year, with net loss narrowing sharply to Rs (183.71) lakhs from Rs (353.11) lakhs. Q4 standalone turned profitable at Rs 8.74 lakhs vs a Rs (403.95) lakhs loss a year ago. Consolidated FY25 revenue grew about 48% to Rs 4,304.58 lakhs on the back of subsidiary Innopharma Healthcare (FY revenue Rs 1,383.92 lakhs), while consolidated net loss was Rs (199.92) lakhs. The board also re-appointed Maheshwari Maheshwari & Co. as internal auditor for FY26 and granted 75,000 stock options to eligible employees under the 2018 ESOP scheme.
Loss narrowed materially and the consolidated business posted strong top-line growth driven by Innopharma, which is mildly positive for shareholders. However, the company remains loss-making at the bottom line and the new ESOP grant will cause some dilution, so the stock is unlikely to see a strong immediate reaction.